(177)Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art

BACKGROUND: Prostate specific membrane antigen (PSMA) ligand labeled with Lutetium-177 (177Lu) is a promising therapeutic option for metastatic castration-resistant prostate cancer (mCRPC). Several prospective and retrospective studies as well as clinical trials are completed or underway. This has u...

Descripción completa

Detalles Bibliográficos
Autores principales: AlSadi, Rahaf, Bouhali, Othmane, Dewji, Shaheen, Djekidel, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249427/
https://www.ncbi.nlm.nih.gov/pubmed/36288537
http://dx.doi.org/10.1093/oncolo/oyac216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249427/
https://www.ncbi.nlm.nih.gov/pubmed/36288537
http://dx.doi.org/10.1093/oncolo/oyac216

Ejemplares similares